Skip to main content
CancerImmunotherapyIndustryMyeloid Cells

Ep. 29: “Immuno-Oncology Therapeutics” Featuring Dr. Michael Alonso

By May 24, 2022January 9th, 2023No Comments

Michael Alonso


Dr. Michael Alonso is a Scientific Co-Founder, and Vice President of Immunology & Pharmacology at Bolt Biotherapeutics, a biotechnology company developing immunotherapies that activate myeloid cells. He discusses targeting tumors by covering them in “eat me” signals, considerations for moving drugs into the clinic, and building teams in biotech.

Featured Products and Resources:

The Immunology Science Round Up

Trade-Offs in Cancer Mutations – Researchers developed a model of hotspot mutations that shows fundamental trade-offs between a tumor’s growth and its visibility to the immune system.

Reversing the T Cell Immune System – To determine how T cell lineage fates are determined in the thymus, scientists generated ‘FlipFlop’ mice with a functionally reversed T cell immune system.

Gut Microbiota and Response to Viral Infection – Suppression of gut microbiota renders mice susceptible to systemic viral infections.

Europe Cancer Immunotherapy Meeting Highlights – Scientists discussed antigenic dominance in lung cancer, next-generation CAR T cell design, and combining CAR T cell therapy with vaccination for solid tumors.

Image courtesy of Dr. Michael Alonso

Subscribe to our newsletter!

Never miss updates about new episodes.